Neurology Medical News about Dopamine Agonists

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

A reassessment of risks and benefits of dopamine agonists in Parkinson's disease
The Lancet Neurology, 09/16/09

Antonini A et al. – Recently, the ocurrence of adverse events such as leg oedema, daytime somnolence, impulse control disorders, and fibrosis have increasingly been recognised. The risks of these potentially serious adverse events must therefore be taken into account and treatment decisions should be based on considerations of risks versus benefits for individual patients.

<< Previous
The risk of stroke in postmenopausal women receiving hormonal...

Next >>
Pharmacology and treatment of neuropathic pains

Dopamine agonist-induced antecollis in Parkinsons disease
Movement Disorders, 11/18/09 Relevance Score: 71%

Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease
Cochrane Reviews, 10/09/09 Relevance Score: 70%

Prolactin and Autoimmunity
Clinical Reviews in Allergy and Immunology, 11/18/09 Relevance Score: 64%

The pragmatic use of apomorphine at the end of life
Palliative Medicine, 10/30/09 Relevance Score: 64%

Potential neuroprotection mechanisms in PD: focus on dopamine agonist pramipexole
Current Medical Research and Opinion, 10/26/09 Relevance Score: 64%